Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: takahashi m, takahashi t. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M, Akiyama Y, Aoki T, Hagiwara K, Takahashi T, Hironaka K, Teranishi F, Osuka F, Takeuchi M, Fujii M, Nakajima T. Kochi M, et al. Among authors: takahashi t. Cancer Chemother Pharmacol. 2013 Nov;72(5):1097-102. doi: 10.1007/s00280-013-2292-9. Epub 2013 Sep 22. Cancer Chemother Pharmacol. 2013. PMID: 24057041 Clinical Trial.
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, Matsumoto H, Kagimura T, Tsuji A. Yoshida M, et al. Among authors: takahashi t. Oncology. 2016;91(1):24-30. doi: 10.1159/000446372. Epub 2016 May 28. Oncology. 2016. PMID: 27229742 Free article. Clinical Trial.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takahashi T, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):585-93. doi: 10.1007/s00280-016-3109-4. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468920 Clinical Trial.
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Oki E, et al. Among authors: takahashi t. Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285591 Free PMC article. Clinical Trial.
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
Masuishi T, Tsuji A, Kotaka M, Nakamura M, Kochi M, Takagane A, Shimada K, Denda T, Segawa Y, Tanioka H, Hara H, Sagawa T, Watanabe T, Takahashi T, Negoro Y, Manaka D, Fujita H, Suto T, Takeuchi M, Ichikawa W, Fujii M. Masuishi T, et al. Among authors: takahashi t. Br J Cancer. 2020 Nov;123(10):1490-1495. doi: 10.1038/s41416-020-01042-w. Epub 2020 Aug 31. Br J Cancer. 2020. PMID: 32863385 Free PMC article. Clinical Trial.
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa YU, Takeuchi M, Ichikawa W, Fujii M. Tanioka H, et al. Among authors: takahashi t. Anticancer Res. 2022 May;42(5):2675-2681. doi: 10.21873/anticanres.15745. Anticancer Res. 2022. PMID: 35489740 Clinical Trial.
Challenge for a better combination with basic evidence.
Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, Tanaka Y. Yoshida K, et al. Among authors: takahashi t. Int J Clin Oncol. 2008 Jun;13(3):212-9. doi: 10.1007/s10147-008-0793-z. Epub 2008 Jun 14. Int J Clin Oncol. 2008. PMID: 18553230 Review.
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Takahashi T, et al. Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2. Int J Clin Oncol. 2013. PMID: 22383023 Clinical Trial.
14,713 results
You have reached the last available page of results. Please see the User Guide for more information.